골다공증 동물 모델에서 골밀도 변화에 관한 카텝신 K 억제제와 부갑상선호르몬 병용요법의 효과 = The Effects of Combination Therapy of Cathepsin K Inhibitor and PTH on Change in Bone Mineral Density in an Animal Model of Osteoporosis

다국어 초록 (Multilingual Abstract)

Background: We hypothesized that combination therapy of cathepsin K inhibitor (CTKi) and human parathyroid hormone (1-34)(teriparatide, PTH) would overcome the coupling phenomenon of bone resorption and formation and thus may rapidly increase bone mass.
Methods: We selected a dose of zoledronic acid (ZA) that had shown similar effects with CTKi on body bone mineral density (BMD) change during the preliminary experiment. Female mice were subjected to ovariectomized (OVX control) or a sham operation (SHAM group). The mice were treated with CTKi (CTKi group), ZA (ZA group), PTH (PTH group) or with a combination of PTH with ZA (ZA + PTH group) or CTKi (CTKi + PTH group) for 8 weeks. Total BMD was measured before the operation and at 4 and 8 weeks.
Results: In the preliminary results, 10 μg/kg of ZA showed similar BMD changes with CTKi. Compared with the OVX control, BMD in the SHAM, ZA, CTKi, PTH, ZA + PTH, and CTKi + PTH groups was significantly increased after treatment. BMD in the CTKi + PTH group, but not in the ZA + PTH group increased more significantly than in the PTH group at the end of treatment. Compared with the OVX control, changes in BMD in the SHAM, ZA, CTKi, PTH, ZA + PTH, and CTKi + PTH groups increased significantly after 8weeks of treatment. The change in BMD in the CTKi + PTH group, but not in the ZA + PTH group was more significantly increased than the change in BMD in the PTH group.
Conclusion: When combined with PTH, CTKi augmented the anabolic action of PTH. Therefore, combination therapy with CTKi and PTH might be a new therapeutic modality capable of overcoming the coupling phenomenon, thereby markedly and rapidly increasing bone mass.

참고문헌 (Reference)

1 Corey E, "Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer" 9 : 295-306, 2003

2 Kavanagh KL, "The molecular mechanism of nitrogencontaining bisphosphonates as antiosteoporosis drugs" 7829-7834, 2006

3 Finkelstein JS, "The effects of parathyroid hormone, alendronate, or both in men with osteoporosis" 349 : 1216-1226, 2003

4 Black DM, "The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis" 349 : 1207-1215, 2003

5 Yamane H, "The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice" 44 : 1055-1062, 2009

6 Goh SK, "Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution" 89 : 349-353, 2007

7 Odvina CV, "Severely suppressed bone turnover: a potential complication of alendronate therapy" 90 : 1294-1301, 2005

8 NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, "Osteoporosis prevention, diagnosis, and therapy" 285 : 785-795, 2001

9 Karsdal MA, "Osteoclasts secrete non-bone derived signals that induce bone formation" 366 : 483-488, 2008

10 Bone HG, "Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density" 25 : 937-947, 2010

11 Eisman JA, "Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect" 26 : 242-251, 2011

12 Canalis E, "Mechanisms of anabolic therapies for osteoporosis" 357 : 905-916, 2007

13 Saftig P, "Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice" 13453-13458, 1998

14 Brömme D, "Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme" 271 : 2126-2132, 1996

15 Cosman F, "Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis" 26 : 503-511, 2011

16 Udell JA, "Effect of the Women’s Health Initiative on osteoporosis therapy and expenditure in Medicaid" 21 : 765-771, 2006

17 Neer RM, "Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis" 344 : 1434-1441, 2001

18 Nishi Y, "Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation" 14 : 1902-1908, 1999

19 Deal C, "Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo- controlled trial" 20 : 1905-1911, 2005

20 Del Fattore A, "Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment" 43 : 315-325, 2006

21 Xiang A, "Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in ovariectomized mice" 40 : 1231-1237, 2007

22 Stoch SA, "Cathepsin K inhibitors: a novel target for osteoporosis therapy" 83 : 172-176, 2008

23 Recker R, "Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients" 19 : 1628-1633, 2004

24 Seeman E, "Bone quality-the material and structural basis of bone strength and fragility" 354 : 2250-2261, 2006

25 Pennypacker B, "Bone density, strength, and formation in adult cathepsin K (-/-) mice" 44 : 199-207, 2009

26 Hughes DE, "Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo" 10 : 1478-1487, 1995

27 Khosla S, "Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research" 22 : 1479-1491, 2007

28 Karsdal MA, "Are nonresorbing osteoclasts sources of bone anabolic activity" 22 : 487-494, 2007

29 Zhou H, "Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice" 32 : 513-520, 2003

30 Kim MK, "An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)- phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats" 318 : 555-562, 2006

31 Bone HG, "Alendronate Phase III Osteoporosis Treatment Study Group: Ten years’ experience with alendronate for osteoporosis in postmenopausal women" 350 : 1189-1199, 2004

32 Segovia-Silvestre T, "Advances in osteoclast biology resulting from the study of osteopetrotic mutations" 124 : 561-577, 2009

33 Gasser JA, "A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats" 39 : 787-795, 2006

34 Lark MW, "A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat" 30 : 746-753, 2002

35 Kumar S, "A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys" 40 : 122-131, 2007